[Amniotic membrane transplantation for the treatment severe acanthamoeba keratitis].
BACKGROUND
It is now possible to treat ocular surface disorders by means of amniotic membrane transplantation. We performed a study to determine the efficacy of this technique in the treatment of severe Acanthamoeba keratitis.


METHODS
We studied six patients with severe, painful, nonhealing Acanthamoeba keratitis who underwent one or two amniotic membrane transplantation procedures between February 2001 and January 2003. Histopathological analysis of the corneal buttons was performed in four cases.


RESULTS
Eight amniotic membrane transplantation procedures were performed. The mean length of follow-up was 14 (range 3-21) months. The mean interval between institution of medical treatment and the procedure was 3.6 months. All patients had progressive stromal lesions caused by an inflammatory reaction. Complete reepithelialization occurred in four cases, and partial healing in two cases. Ocular inflammation and tissue destruction were decreased in all cases, pain was lessened in five cases, and corneal neovascularization was decreased in four cases. No postoperative complications were observed. Amniotic membrane was observed under dysplastic corneal epithelium on histologic examination.


CONCLUSIONS
Amniotic membrane transplantation may be a safe and effective treatment of severe Acanthamoeba keratitis, particularly during the inflammation phase. It may permit penetrating keratoplasty to be delayed.
Bourcier
Tristan
T
Du Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France. bourcier@quinze-vingts.fr
Patteau
Fabienne
F
Borderie
Vincent
V
Baudrimont
Marie
M
Rondeau
Nicolas
N
Bonnel
Sébastien
S
Chaumeil
Christine
C
Laroche
Laurent
L
D015823:Acanthamoeba Keratitis / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D000328:Adult; D000650:Amnion / Q000637:transplantation*; D001645:Biguanides / Q000627:therapeutic use; D001684:Biological Dressings; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014792:Visual Acuity
D001645:Biguanides; D005938:Glucocorticoids; C031233:polihexanide